By combining DNA instructions with our proprietary delivery platform, we are aiming for digital-like precision in how the immune system is retrained. With the first ADI product candidate ADI-100, we ...
Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results